1
|
Pavelek Z, Novotný M, Klímová B, Peterka M, Potužník P, Kövári M, Vališ M. DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment. Curr Med Res Opin 2021; 37:589-596. [PMID: 33538199 DOI: 10.1080/03007995.2021.1880886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
PURPOSE The aim of this article is to provide unique and detailed data on how patients rate the RebiSmart 2.0 in the specific User Study Questionnaire (USQ) domains, and the relationship between their rating and individual level of disability, baseline demographic/socioeconomic factors, and adherence. PATIENTS AND METHODS Twelve-month, phase IV, observational, multicenter study (no placebo or comparator) to evaluate the ease of use of the RebiSmart autoinjector for self-injection during treatment of CIS/RRMS subjects with Rebif 44 mcg sc three times a week by USQ. A total of 290 subjects participated in the study, with 249 (85.86%) completing the entire study period. RESULTS The endpoint results demonstrated a very high proportion (>95%) of patients with a positive evaluation of the overall convenience of RebiSmart at each study visit. At the end of the study, all patients would recommend the device to others who need Rebif therapy. The proportion of patients rating the RebiSmart ease of use by individual domains (self-injection steps, changing the cartridge, using the device away from home) as "very easy to use" or "easy to use" and the proportion of patients rating the RebiSmart functions as "helpful" or "very helpful" were more than 80% for each domain at each study visit. CONCLUSION These findings are in line with the potential benefits of RebiSmart to treatment adherence. They demonstrate an overall, very good perception of the device by patients and its individual functions.
Collapse
Affiliation(s)
- Zbyšek Pavelek
- Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Michal Novotný
- Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Blanka Klímová
- Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Marek Peterka
- Department of Neurology, University Hospital Plzen, Plzen, Czech Republic
| | - Pavel Potužník
- Department of Neurology, University Hospital Plzen, Plzen, Czech Republic
| | - Martina Kövári
- Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
| | - Martin Vališ
- Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| |
Collapse
|
2
|
Wray S, Hayward B, Dangond F, Singer B. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study. Expert Opin Drug Deliv 2017; 15:127-135. [PMID: 29206056 DOI: 10.1080/17425247.2018.1407755] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND For interferon beta-1a subcutaneously three times weekly (IFN β-1a SC tiw), administration options include manually injected prefilled syringes; a preassembled, single-use autoinjector; and a reusable autoinjector. This study evaluated patient-perceived ease of use of two injection devices. RESEARCH DESIGN AND METHODS REDEFINE, a Phase IV, multicenter crossover study, randomized patients with multiple sclerosis and ≥5 weeks' IFN β-1a 44 μg SC tiw use to 4 weeks using a single-use autoinjector, then 4 weeks using a reusable autoinjector, or vice versa. The primary endpoint was the proportion rating each 'easy' or 'very easy', with/without regard to previous device experience. RESULTS Of 97 randomized patients, 29 had most recent experience with manual injection; 23 with single-use autoinjector; and 45 with reusable autoinjector. 68.4% found using the single-use autoinjector very easy or easy, versus 77.9% for the reusable device (difference -9.5%; p = 0.200). 40.0% versus 29.5% found the respective devices very easy (difference 10.5%; p = 0.203). CONCLUSIONS Most patients found both autoinjectors easy or very easy to use. Having two viable options may help accommodate patient preferences. Ease of administration and patient satisfaction relates to adherence; satisfied patients may more likely be adherent. TRIAL REGISTRATION The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT02019550).
Collapse
Affiliation(s)
- Sibyl Wray
- a Hope Neurology Multiple Sclerosis Center , Knoxville , TN , USA
| | | | | | - Barry Singer
- c The MS Center for Innovations in Care, Missouri Baptist Medical Center , St. Louis , MO , USA
| |
Collapse
|
3
|
Limmroth V, Reischl J, Mann B, Morosov X, Kokoschka A, Weller I, Schreiner T. Autoinjector preference among patients with multiple sclerosis: results from a national survey. Patient Prefer Adherence 2017; 11:1325-1334. [PMID: 28831243 PMCID: PMC5548304 DOI: 10.2147/ppa.s137741] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
PURPOSE Autoinjectors are well-established in supporting multiple sclerosis (MS) therapy. This market survey was aimed at investigating patients' rating of three devices for subcutaneous interferon beta formulations: the electronic autoinjectors Betaconnect® and RebiSmart™ as well as the mechanical ExtaviPro™ device. PATIENTS AND METHODS Organization and conduction of structured face-to-face interviews in five German cities were managed through an independent external market research company. After questionnaire validation (n=15), 85 participants currently either using the Betaconnect (n=39), the RebiSmart (n=36) or the ExtaviPro injector (n=10) were asked 22 questions in the same order. First, patients named their current device in use, watched the corresponding instruction video, and were queried about their device. Second, patients were asked about their opinion of an ideal autoinjector. Third, instruction videos for the two non-used devices were presented and participants could dummy-inject into a pillow. Last, patients evaluated device features and indicated their preferred autoinjector. RESULTS Before having been presented the two other autoinjectors not in use, evaluation of patients' satisfaction with their own device revealed that 82% of the Betaconnect users, 67% of the RebiSmart and 60% of the ExtaviPro users were highly satisfied. All patients desired some improvement of their own device particularly concerning optimization of size and handling. Subsequent to testing and watching instruction videos of all devices, the Betaconnect received the best rating regarding different functions. Finally, participants indicated their preferred autoinjector, provided their own medication was suitable for all three devices: 56.5% of the participants (n=48/85) chose the Betaconnect, 36.5% the RebiSmart (n=31/85), and 5% the ExtaviPro device (n=4/85); 2% did not answer (n=2/85). CONCLUSION In this survey, the Betaconnect device was the preferred autoinjector and may currently best meet patients' needs. As it was closest to participants' opinion of an ideal device, the Betaconnect might contribute to treatment adherence. Our results need to be confirmed in further studies.
Collapse
Affiliation(s)
- V Limmroth
- Clinic for Neurology and Palliative Medicine, Municipal Hospital Köln-Merheim, Cologne
| | | | - B Mann
- IFAK Institute GmbH & Co. KG, Taunusstein, Germany
| | | | | | | | - T Schreiner
- Bayer Vital GmbH, Leverkusen
- Correspondence: T Schreiner, Bayer Vital GmbH, Kaiser-Wilhelm-Allee 70, 51373 Leverkusen, Germany, Tel +49 214 305 1049, Fax +49 214 305 1056, Email
| |
Collapse
|
4
|
Fernández O, Arroyo R, Martínez-Yélamos S, Marco M, Merino JAG, Muñoz D, Merino E, Roque A. Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis. PLoS One 2016; 11:e0160313. [PMID: 27526201 PMCID: PMC4985132 DOI: 10.1371/journal.pone.0160313] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Accepted: 07/18/2016] [Indexed: 12/26/2022] Open
Abstract
The effectiveness of disease-modifying drugs in the treatment of multiple sclerosis is associated with adherence. RebiSmart® electronic device provides useful information about adherence to the treatment with subcutaneous (sc) interferon (IFN) β-1a (Rebif®). The aim of the study was to determine long-term adherence to this treatment in patients with relapsing-remitting multiple sclerosis (RRMS). This retrospective multicentre observational study analysed 258 patients with RRMS who were receiving sc IFN β-1a (Rebif®) treatment by using RebiSmart® until replacement (36 months maximum lifetime) or treatment discontinuation. Adherence was calculated with data (injection dosage, time, and date) automatically recorded by RebiSmart®. Patients in the study had a mean age of 41 years with a female proportion of 68%. Mean EDSS score at start of treatment was 1.8 (95% CI, 1.6-1.9). Overall adherence was 92.6% (95% CI, 90.6-94.5%). A total of 30.2% of patients achieved an adherence rate of 100%, 80.6% at least 90%, and only 13.2% of patients showed a suboptimal adherence (<80%). A total of 59.9% of subjects were relapse-free after treatment initiation. Among 106 subjects (41.1%) who experienced, on average, 1.4 relapses, the majority were mild (40.6%) or moderate (47.2%). Having experienced relapses from the beginning of the treatment was the only variable significantly related to achieving an adherence of at least 80% (OR = 3.06, 1.28-7.31). Results of this study indicate that sc IFN β-1a administration facilitated by RebiSmart® could lead to high rates of adherence to a prescribed dose regimen over 36 months.
Collapse
Affiliation(s)
- O. Fernández
- Hospitales Universitarios Regional de Málaga y Virgen de la Victoria, Universidad de Málaga, IBIMA
| | - R. Arroyo
- Hospital U. Clínico San Carlos, Madrid
| | | | - M. Marco
- Corporació Sanitaria Parc Taulí, Barcelona
| | | | | | | | | | | |
Collapse
|
5
|
Ziemssen T, Sylvester L, Rametta M, Ross AP. Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™). Neurol Ther 2015; 4:125-36. [PMID: 26662362 PMCID: PMC4685867 DOI: 10.1007/s40120-015-0036-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Indexed: 11/12/2022] Open
Abstract
Introduction Multiple sclerosis (MS) typically requires life-long management with disease-modifying therapies (DMTs). Many DMTs require regular self-injection, and can be associated with injection site reactions, pain, and needle/injection phobia—but these can be addressed by improvements in autoinjector design. The aim of this study was to investigate patient satisfaction and preference for BETACONNECT™ (Bayer Pharma AG), a novel interferon beta-1b autoinjector. Methods Patients in Germany performing self-injections using BETACONNECT took part in the study. Data were collected through an online 15-min structured survey. Participants rated their experience with BETACONNECT on a 6-point scale and those satisfied with BETACONNECT were asked to describe the reason using a free-text box. Results One-hundred and eighteen patients with MS completed the survey. Ninety percent preferred BETACONNECT to their previous injection method (only 4% previously used manual injections, so most had previously used other autoinjectors). Ninety-two percent were very confident/confident in their ability to perform an injection using BETACONNECT. The most common free-text responses to “Why are you satisfied with the BETACONNECT™ autoinjector?” were ease of use (46%), less irritation/pain at the injection site (33%), and smoother injections (24%). Features considered most useful were automated injections (98%), adjustable injection speed (98%), and adjustable injection depth (98%). Ninety-seven percent thought it was easy to know when an injection was complete and 95% agreed/strongly agreed it was easy to learn to use the autoinjector. Seventy-three percent agreed that the quietness and effortlessness of the BETACONNECT reduced their level of injection anxiety, 92% that its size and shape makes it easy to handle during injections, and 67% that it decreases injection site pain. Eighty percent of those using the reminder function thought they were less likely to miss an injection. Conclusion Patients with MS self-injecting interferon beta-1b expressed a high level of satisfaction and preference for BETACONNECT. Thus, BETACONNECT represents a valid option to improve patients’ overall injection experience. Funding Bayer HealthCare Pharmaceuticals. Electronic supplementary material The online version of this article (doi:10.1007/s40120-015-0036-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Tjalf Ziemssen
- Department of Neurology, Centre for Clinical Neurosciences, University Hospital Carl Gustav Carus at the Technical University of Dresden, Dresden, Germany.
| | | | - Mark Rametta
- Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
| | | |
Collapse
|
6
|
Weller I, Saake A, Schreiner T, Vogelreuter J, Petroff N. Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b. Patient Prefer Adherence 2015; 9:951-9. [PMID: 26185425 PMCID: PMC4501165 DOI: 10.2147/ppa.s85917] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
PURPOSE Multiple sclerosis (MS) is a chronic demyelinating, degenerative disease requiring long-term treatment. Patient adherence to treatment may be challenging in such scenarios, especially since treatment often involves self-injection, for example, with interferon beta-1b during therapy. BETACONNECT™ is a novel electronic autoinjector for patient support in interferon beta-1b administration. The purpose of this survey was to assess patient satisfaction with the BETACONNECT™ device and its features. PATIENTS AND METHODS A total of 2,299 MS patients using the BETACONNECT™ device were asked to participate in a survey in October 2014. All of these candidates participated in the BETAPLUS(®) program and had provided written informed consent. The participants were asked to answer 13 device-related questions. RESULTS Of these candidates, 1,365 replied to the questionnaire, with more than 60% of the participants being 40-59 years of age. Among them, 69% were women and 21% were men (10% not specified). Approximately half of the participants received treatment with interferon beta-1b for more than 5 years. Most participants (85%) had used self-injection devices before, with 59% previously using BETACOMFORT(®), 23% using BETAJECT(®) Comfort, and 3% using BETAJECT(®) Lite, while less than 4% manually injected interferon beta-1b. The majority of the participants had received the BETACONNECT™ device from a BETAPLUS(®) nurse (87%) and 48% had already used the device for more than 2 months (49% for 2 months or less). Among the participants, more than 90% evaluated the BETACONNECT™ device as "very helpful" or "helpful" in supporting their interferon beta-1b therapy with only marginal sex differences. Features that were rated "very important" by more than half of the participants included adjustability of injection speed and depth, contact sensor for avoidance of unintentional release, optical and acoustic signals, and rechargeable battery. CONCLUSION The vast majority of patients rated the BETACONNECT™ device as very helpful or helpful for their treatment with interferon beta-1b, and many considered most features as "very important". In conclusion, usage of the BETACONNECT™ autoinjector may facilitate interferon beta-1b therapy and support adherence to long-term therapeutic regimen.
Collapse
Affiliation(s)
- Ivonne Weller
- Bayer Vital GmbH, Leverkusen, Germany
- Correspondence: Ivonne Weller, Bayer Vital GmbH, Kaiser-Wilhelm-Allee 70, 51373 Leverkusen, Germany, Tel +49 214 30 51143, Fax +49 214 30 51056, Email
| | | | | | | | | |
Collapse
|
7
|
Hupperts R, Becker V, Friedrich J, Gobbi C, Salgado AV, Sperling B, You X. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin Drug Deliv 2014; 12:15-25. [DOI: 10.1517/17425247.2015.989209] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
8
|
Lugaresi A. RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence. Expert Opin Drug Deliv 2012; 10:273-83. [DOI: 10.1517/17425247.2013.746311] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|